Objectives: The objective of the present study was to analyse the use of 100 g aspirin dose as prevention method for preeclampsia in high risk pregnant patients. Methods: A retrospective cohort study was performed in high risk pregnant patients with a blood pressure protocol, and the use of 100 mg of aspirin vs. its non-use was evaluated in the incidence of PREEC. Estimations between the two groups were performed with and without variable adjustment by means of binary logistic regression models. Results: 633 high risk pregnant patients were evaluated. The average age was 30±7 years old, and 25±8 weeks of pregnancy. 281 women (44.3 %) within this group received aspirin. The total prevalence of PREEC in our sample was 151 pregnant women (23.8 %). Pregnant patients under the aspirin treatment developed less PREEC events (19.2% vs 27.5%, p=0.019); with OR not adjusted 0.62 (IC95% 0.43-0.91 p= 0.017). The risk was similar when it was adjusted by age, preeclampsia history, diabetes mellitus and chronic high blood pressure. (OR adjusted 0.63 IC95% 0.43-0.92 p= 0.017). Conclusions: The use of 100 mg of aspirin a day before the 20th week of pregnancy in high risk pregnant patients decreased the risk of developing PREEC, regardless the age and risk factors. Universidad Nacional de Córdoba.
Objectives: The objective of the present study was to analyse the use of 100 g aspirin dose as prevention method for preeclampsia in high risk pregnant patients. Methods: A retrospective cohort study was performed in high risk pregnant patients with a blood pressure protocol, and the use of 100 mg of aspirin vs. its non-use was evaluated in the incidence of PREEC. Estimations between the two groups were performed with and without variable adjustment by means of binary logistic regression models. Results: 633 high risk pregnant patients were evaluated. The average age was 30±7 years old, and 25±8 weeks of pregnancy. 281 women (44.3 %) within this group received aspirin. The total prevalence of PREEC in our sample was 151 pregnant women (23.8 %). Pregnant patients under the aspirin treatment developed less PREEC events (19.2% vs 27.5%, p=0.019); with OR not adjusted 0.62 (IC95% 0.43-0.91 p= 0.017). The risk was similar when it was adjusted by age, preeclampsia history, diabetes mellitus and chronic high blood pressure. (OR adjusted 0.63 IC95% 0.43-0.92 p= 0.017). Conclusions: The use of 100 mg of aspirin a day before the 20th week of pregnancy in high risk pregnant patients decreased the risk of developing PREEC, regardless the age and risk factors. Universidad Nacional de Córdoba.
Authors: C Luke Dixon; Caroline Marrs; Maged M Costantine; Luis D Pacheco; George R Saade; Giuseppe Chiossi Journal: Am J Perinatol Date: 2017-04-26 Impact factor: 1.862
Authors: Martin R Salazar; Walter G Espeche; Betty C Leiva Sisnieguez; Eduardo Balbín; Carlos E Leiva Sisnieguez; Rodolfo N Stavile; Carlos E March; Florencia Grassi; Claudia Santillan; Susana Cor; Horacio A Carbajal Journal: J Hypertens Date: 2016-11 Impact factor: 4.844
Authors: Jillian T Henderson; Evelyn P Whitlock; Elizabeth O'Connor; Caitlyn A Senger; Jamie H Thompson; Maya G Rowland Journal: Ann Intern Med Date: 2014-05-20 Impact factor: 25.391
Authors: Daniel L Rolnik; David Wright; Liona C Poon; Neil O'Gorman; Argyro Syngelaki; Catalina de Paco Matallana; Ranjit Akolekar; Simona Cicero; Deepa Janga; Mandeep Singh; Francisca S Molina; Nicola Persico; Jacques C Jani; Walter Plasencia; George Papaioannou; Kinneret Tenenbaum-Gavish; Hamutal Meiri; Sveinbjorn Gizurarson; Kate Maclagan; Kypros H Nicolaides Journal: N Engl J Med Date: 2017-06-28 Impact factor: 91.245
Authors: Piya Chaemsaithong; Diana Cuenca-Gomez; María N Plana; María M Gil; Liona C Poon Journal: Am J Obstet Gynecol Date: 2019-09-05 Impact factor: 8.661
Authors: David Wright; Liona C Poon; Daniel L Rolnik; Argyro Syngelaki; Juan Luis Delgado; Denisa Vojtassakova; Mercedes de Alvarado; Evgenia Kapeti; Anoop Rehal; Andrea Pazos; Ilma Floriana Carbone; Vivien Dutemeyer; Walter Plasencia; Nikos Papantoniou; Kypros H Nicolaides Journal: Am J Obstet Gynecol Date: 2017-09-06 Impact factor: 8.661